AddedRisk Factors
If we achieve success in our clinical trials, we would need to scale our operations to support commercialization, and we may encounter difficulties in managing this growth.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
While we do not anticipate significant growth in our workforce or the scope of our operations in the near-term, our long-term strategy depends on the successful development and subsequent commercialization of our product candidates. If we achieve positive clinical results, we expect to experience a period of rapid scaling to build the necessary development, regulatory, sales, marketing, and distribution capabilities. To manage this future growth, we must continue to improve our managerial, operational, and financial systems. Shifting from a research-focused organization to a commercial-stage company presents significant operational and cultural challenges. We may not be able to effectively manage this future expansion or recruit and train the additional qualified personnel required for commercialization. If we are unable to manage this long-term scaling effectively, our ability to generate revenue from our product candidates would be compromised.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
We may acquire additional businesses, products, form strategic alliances, or create joint ventures and we may not realize the benefits of such transactions.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
We have recently undertaken a cost reduction plan and may do so again in the future. The assumptions underlying these activities may prove to be inaccurate, or we may fail to achieve the expected benefits therefrom.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedRisk Factors
We cannot provide any assurances that any of our or our licensors’ pending or future patent applications will issue, or that any pending or future patent applications that mature into issued patents will include claims with a scope
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The failure to integrate successfully the businesses of Recursion and Exscientia in the expected timeframe would adversely affect Recursion’s future business and financial performance
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The combination of two independent companies is a complex, costly and time-consuming process. As a result, the combined company will be required to devote significant management attention and resources to integrate the business practices and operations of Exscientia and Recursion. The integration process may disrupt the business of either or both of the companies and, if implemented ineffectively, could preclude realization of the full benefits expected by Exscientia and Recursion business combination. The failure of Recursion to meet the challenges involved in successfully integrating the operations of Exscientia and Recursion or otherwise to realize the anticipated benefits of the business combination could cause an interruption of the activities of Recursion and could seriously harm its results of operations. In addition, the overall integration of the two companies may result in
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
material unanticipated problems, expenses, liabilities, competitive responses, loss of customer relationships and diversion of management’s attention, and may cause Recursion’s stock price to decline. The difficulties of combining the operations of Recursion and Exscientia include, among others:
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•coordinating geographically separate organizations, including extensive operations outside of the U.S.;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the potential diversion of management’s focus and resources from other strategic opportunities and from operational matters;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•performance shortfalls at one or both of the companies as a result of the diversion of management’s attention caused by integrating the companies’ operations;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•retaining existing business relationships and executing new strategic or commercial relationships;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the disruption of, or the loss of momentum in, each company’s ongoing business or inconsistencies in standards, controls, systems, procedures and policies;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the possibility of faulty assumptions underlying expectations regarding the integration process;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•consolidating corporate and administrative infrastructures and eliminating duplicative operations;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware, is the exclusive forum for the following, except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court, and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination, which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction:
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
(Valence) in May 2023, we issued 12.4 million shares of our Class A common stock or securities convertible or exchangeable into Class A common stock and stock; in November 2024, we issued approximately 102.1 million shares of our Class A Common Stock common stock in connection with our business combination with Exscientia plc (Exscientia). (Exscientia); and in July and August 2025 we issued an aggregate of 3.9 million shares of our Class A common stock in connection with our purchase of RallyBio Corporation’s 50% membership interest in the ENPP1 joint venture, RE Ventures I, LLC.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Bayer Agreement, the Roche and Genentech Agreement, the Merck Agreement, and the Sanofi Agreement are some of our key collaborations, and there is no assurance that these collaborations will continue past their current terms, on favorable terms or at all, or that at any time while the collaborations are in effect the parties will operate under the agreements without disputes.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of patents issuing from those patent applications, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
These and other future further regulations, legislation, sanctions, or restrictions could adversely impact our current or future third-party arrangements with companies such as WuXi AppTec AppTec, which in turn could delay or impact clinical trials trials, add expenses or unforeseen burdens to the process of contracting with service providers, and consequently could delay or obstruct successful commercialization of our drug candidates. candidates or reduce our profitability.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or DGCL that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of Class A common stock and could also affect the price that some investors are willing to pay for our stock.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Other causes of uncertainty include the effects of new tariffs proposed implemented by the President against United States on imports from Mexico and Canada. Canada that do not qualify for duty-free treatment under the U.S.-Mexico-Canada Agreement.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any of the foregoing could have a material adverse effect on our business, results of operations, reputation, and prospects, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); interruptions or stoppages of data collection needed to train our algorithms; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
The transition to lower greenhouse gas emissions technology, the effects of carbon pricing, and changes in public sentiment, regulations, taxes, public mandates, or requirements and increases in climate-related lawsuits, insurance premiums, and implementation of more robust disaster recovery and business continuity plans could increase costs to maintain or resume our operations or achieve any sustainability commitments we make, which would negatively impact our results of operations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
If at any time we are unable to conclude that our disclosure controls and procedures and internal control over financial reporting are effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, or if we are unable to remediate any existing weaknesses or deficiencies in a timely manner or at all, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of shares of our Class A common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, the SEC, or other regulatory authorities.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
(Tempus) in payment for license fees under the terms of that certain Master Agreement entered into by and between us and Tempus (the Tempus Agreement) Agreement)—including 7.1 million shares in November 2025, 3.5 million shares in December 2024, and 3.2 million shares in December 2023—and may issue additional shares in the future under the Tempus Agreement.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our failure to become and remain profitable would eventually depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, develop a pipeline of drug candidates, enter into collaborations, or even continue our operations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We expect our operating expenses to significantly increase as we continue to invest in research and development efforts and the commencement and continuation of clinical trials of our existing and future drug candidates.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We cannot be certain that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships that leverage our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. All of our technologies are designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Summary of Business Highlights: Driving a diversified pipeline powered by the end-to-end AI-native Recursion OS - wholly-owned and partnered programs
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
2025 Wholly Owned Pipeline Achievements: Advancing programs with strong therapeutic rationale, powered by the Recursion OS
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•REC-4881 (MEK1/2): Provided the first clinical validation of the Recursion OS from a novel phenotypic insight, with positive preliminary efficacy results from the ongoing Phase 2 portion of the TUPELO study in FAP, a disease with no approved pharmacotherapies
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
◦REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12).
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
◦After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baseline.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
◦REC-4881 (4 mg QD) has a safety profile consistent with MEK1/2 inhibition, with the majority of treatment-related adverse events being Grade 1 or 2, Grade 3 events occurring in 15.8% of the safety-evaluable patients, and no Grade ≥4 TRAEs reported to date. The most frequent TRAEs (at ≥10%) included dermatitis acneiform / rash and blood CPK increase.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•REC-617 (CDK7): A potential best-in-class CDK7 inhibitor optimized for improved therapeutic index using our AI-driven precision design platform and identified as lead candidate in under 11 months with 136 novel compounds synthesized, delivered further Phase 1/2 results in November 2025, demonstrating promising safety and preliminary efficacy signals. The program is currently advancing in ongoing Phase 1 combination studies in 2L+ platinum-resistant ovarian cancer (PROC) alongside Phase 2 monotherapy expansion.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•REC-7735 (PI3Kα H1047R): Recursion announced new preclinical efficacy data on REC-7735, a potential best-in-class PI3K⍺ H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. Current pan-PI3K⍺ inhibitors lack selectivity over the wild-type protein, resulting in metabolic liabilities, including hyperglycemia, that often necessitate dose reductions in a significant portion of non diabetic patients and the exclusion entirely of diabetic patients from treatment. REC-7735 demonstrates >100-fold selectivity for the H1074R mutation over WT PI3K⍺ suggesting potential improved tolerability and is currently in IND-enabling studies.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•REC-1245 (RBM39): Early Phase 1 safety and PK monotherapy data expected in 1H26
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
◦Initiate FDA engagement in 1H26 to align on a potential registration pathway for REC-4881, alongside ongoing dosing optimization and expansion of TUPELO to include patients aged 18+ to support a broader development strategy.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•REC-7735 (PI3Kα H1047R) and REC-102 (ENPP1): IND-enabling studies ongoing; data-driven go/no-go decision on Phase 1 initiation expected in 2H26
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedMD&A
Recursion is a leading clinical stage TechBio company with a mission to decode biology to radically improve lives. We aim to achieve our mission by industrializing drug discovery using the Recursion Operating System (OS), a vertical platform of diverse technologies that enables us to map and navigate trillions of biological, chemical, and patient-centric relationships utilizing approximately 65 petabytes of proprietary data. The Recursion OS integrates ‘Real World’ data generated in our own wet-laboratories or by select partners and a ‘World Model’ which is a collection of AI computational models we also build in-house. Today, our scaled ‘wet-lab’ biology, chemistry, and patient-centric experimental data feed our ‘dry-lab’ computational tools to identify, validate, and translate therapeutic insights, which we can then validate in our wet-lab to both advance drug discovery programs and to generate data to further refine our world model.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
There are a few key factors that differentiate Recursion from other technology-enabled drug discovery companies.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
1.Recursion has built a full-stack platform utilizing many biology, chemistry, and patient-centric proprietary datasets and modular tools to industrialize drug discovery, while most other competitor companies rely on a point solution to solve one important step in drug discovery. We recognize that drug discovery is made up of many steps, and a point solution is insufficient to generate efficiencies across the entire process. To decode biology, we must construct a full-stack technology platform capable of integrating and industrializing many complex workflows.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
2.Recursion integrates wet-lab and dry-lab capabilities in-house to create a virtuous cycle of iteration. Fit-for-purpose wet-lab experimental data are translated by dry-lab digital tools into in silico hypotheses and testable predictions, which in turn generates more wet-lab data from which improved predictions can be made. Recursion is well positioned compared to companies of a similar stage either focused more specifically on the wet-lab only (traditional biotech or pharma companies) or dry-lab only (companies facing rapidly commoditized algorithms and a challenge differentiating on non-proprietary data).
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
3.Recursion has achieved a significant scale with respect to its scientific, technological, and business endeavors. With eight clinical-stage programs, an exciting preclinical pipeline, four of the largest discovery partnerships in the biopharma industry with Roche-Genentech, Sanofi, Bayer and Merck KGaA, and four technology-focused partnerships, Recursion has achieved a scale, level of integration, and stage that few other TechBio companies have.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We leverage the Recursion OS to deliver value in three ways: 1) our own pipeline of clinical and preclinical potential medicines focused in precision oncology, rare disease and other niche areas of unmet need; 2) by discovering new medicines with large biopharmaceutical companies in some of the biggest areas of unmet need in medicine like neuroscience and inflammation; and 3) by leveraging our tools, technology and data for the benefit of other partners in targeted and limited ways.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We are actively advancing key catalysts in our clinical pipeline while demonstrating significant progress in addressing high unmet medical needs. At the same time, we continue to validate various components of the Recursion OS, which has played a role in advancing every program in our portfolio, reinforcing its potential to accelerate drug discovery and development.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
In 2024, we accelerated the next wave of AI-driven drug discovery and development, delivering key milestones across multiple clinical programs, advancing our transformative partnerships, unveiling major breakthroughs in foundation models and by consolidating some of the best tools, technologies and talent into what we believe is the leading company in the burgeoning field of TechBio.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•REC-617: A potential best-in-class CDK7 inhibitor optimized using our AI platform, delivered early Phase 1/2 results demonstrating promising safety and preliminary efficacy, including a durable partial response in a late-stage metastatic ovarian cancer patient and stable disease across four other patients with solid tumors (e.g. CRC, NSCLC)
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•REC-994: A potential first-in-disease oral superoxide scavenger for symptomatic CCM, confirmed safety and tolerability of chronic dosing in a Phase 2 study, with exploratory analyses suggesting lesion volume reduction on MRI and symptom stabilization as evaluated by change in mRS scores
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•Clinical Advancements and Regulatory Milestones: Initiated three clinical studies: DAHLIA (Phase 1/2, REC-1245 for solid tumors and lymphoma), TUPELO (Phase 1b/2, REC-4881 for FAP), and ALDER (Phase 2, REC-3964 for recurrent C. difficile infection), received IND clearance for REC-4539 (small cell lung cancer), CTA approval for REC-3565 (b-cell malignancies), and progressed REC-4209 (idiopathic pulmonary fibrosis) to IND-enabling studies
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•Roche and Genentech: Generated whole-genome and chemical perturbation maps in a gastrointestinal oncology indication and a whole genome neuroscience phenomap. The neuro phenomap resulted in the exercise of a $30M milestone
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, the decrease in interest income other income, net compared to the prior year related to a decrease in earnings our loss on cash disposal of Exscientia GmbH of $4.5 million and cash equivalents in money market funds. our Vienna lease termination fee of $5.2 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by financing activities during the year ended December 31, 2024 2025 primarily included proceeds of $300.4 $528.9 million from Class A common stock issuances related to our June 2024 public offering at-the-market offerings (ATMs) which was partially offset by our repayment of Class A common stock long-term debt and our at-the-market offering (ATM). finance lease liabilities of $8.4 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, the increase in general research and administrative expense development expenses compared to the prior year was primarily driven by increases in salaries and wages Tempus record purchases of $21.1 $49.9 million, transaction costs acquired IPR&D purchases of $20.5 $22.8 million and the inclusion of Exscientia’s results of $11.3 $102.4 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2023, 2025, the increase decrease in general and administrative expense compared to the prior year was primarily driven by an increase in salaries and wages of $12.4 million and increases in legal, software and depreciation expense. not significant.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We had cash and Cash, cash equivalents of $594.3 and restricted cash totaled $753.9 million as of December 31, 2024. 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Cash and Cash, cash equivalents and restricted cash totaled $594.3 $753.9 million and $391.6 $603.0 million as of December 31, 2024 2025 and 2023, 2024, respectively.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
In August 2023, Recursion entered into an Open Market Sales Agreement with Jefferies LLC to provide for the offering, issuance and sale of up to an aggregate amount of $300.0 million of its Class A common stock of which $132.8 million remain available for future sales. Common stock.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Cash used by in operating activities increased during the year ended December 31, 2024 2025 as a result of higher costs incurred for research and development and general and administrative primarily due to the Company’s expansion and upgraded capabilities. acquisition of Exscientia.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The Group had incurred $16.3 $21.7 million relating to the Pandemic Preparedness Program as at December 31, 2024, with a total outstanding commitment of $53.7 million. 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Platform, which refers primarily to expenses related to screening of product candidates through hit identification; identification, this also includes expenses related to Tempus records purchased;
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
See Note 4, “Acquisitions” to the Consolidated Financial Statements for additional details. details related to the Exscientia acquisition and Exscientia GmbH disposal.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Additionally, as of December 31, 2024, since 2023, we have also received proceeds of $217.0 $74.0 million from our strategic partnerships.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new